Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT04873258
Recruiting Observational

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

NCT04873258 · tracked via the Priya Life Science UK tracker
Sponsor
Richmond Research Institute
Phase
Observational
Started
2019-09-27
Last updated
2026-08-19

Condition(s) studied

HealthyFatty LiverMASLDMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseObesity and Obesity-related Medical Conditions

Investigational drug(s) / intervention(s)

Bioimpedence Vector Analysis

Bioimpedence Vector Analysis: Bioimpedence vector analysis

Study summary

A generic screening study to establish structural and/or functional baselines of specific organs.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent. 2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations. 3. An understanding, ability and willingness to fully comply with project procedures and restrictions. For PART B only: 1\. With a known history of MASLD as evidenced either of: 1. GP diagnosis on HCF 2. Documented Fibroscan or liver US demonstrating MASLD Exclusion Criteria: 1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other) 2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease) 3. Alcohol consumption \>30 units per week 4. An Implanted cardiac devices

Primary outcome measure(s)

  • Establishment of Classification Tool for Use in Clinical Trials — Study duration (1 year)
    The success of the final classification tool (as measured by area under the receiver operator curve (AUROC). The initial measure to generate the dataset will be the presence or absence of MASLD on liver USS.

Trial sites (1)

FacilityCityRegionStatus
Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge London London Recruiting

More Richmond Research Institute trials in the UK

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care Recruiting
Serological and PCR Testing for COVID-19 Recruiting
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY Recruiting
Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations Recruiting

Other trials for the same condition

Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants Recruiting
Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes Active, not recruiting
Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet Recruiting
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants Active, not recruiting
A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04873258 on ClinicalTrials.gov ↗ ← All trials in the UK